- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint about Sunosi website links, mobile prescribing info and dosing claim. Panel found no breach for external-link clarity or dosing claim, but…
Complaint alleged a Seretide Evohaler banner claim was misleading on age/indication and that “PI” was unclear. PMCPA ruled no breach across all…
Complaint about 60 videos on LEO’s Global YouTube. Most out of UK Code scope, but breaches found for an HCP symposium video…
Complaint about transparency of GSK sponsorship of a GP Online article and alleged disguised promotion on a low-carbon inhalers HCP website. Panel…
A gated UK HCP “educational” site hosted an article indirectly promoting Abilify Maintena, including off-label depression messaging and missing mandatory info. PMCPA…
Complaint about two Lixiana (edoxaban) websites. Most allegations not proven, but two webpage elements were ruled misleading: “lactose not listed as an…
A senior UK employee ‘liked’ LinkedIn posts about investigational/US-approved medicines and a Botox post. PMCPA ruled pre-licence promotion and public promotion of…
Complaint alleged Symbicort cost-calculator webpage lacked prescribing information and generic name and breached a prior undertaking. Panel and Appeal Board found the…
Lilly’s ‘Barber’s Box’ slide deck comparing GLP‑1RAs was ruled misleading: shaded comparative boxes and selective CVOT subgroup messaging implied advantages without adequate…
PMCPA found AstraZeneca’s Symbicort dosing web copy misleading due to omitted max dose/SPC warning (Clause 2 censure). Separate breaches on Trixeo site…
Four Eliquis (apixaban) patient booklets on a company website weren’t updated after SPC changes. Panel found misleading omissions/inaccuracies (Clause 6.1) and failure…
Panel said Daiichi Sankyo’s patient-organisation “cholesterol test” campaign was a contract for services, making the company responsible for materials. Some public educational…
A post-prescription patient website for Nilemdo/Nustendi was ruled to promote Nustendi to patients prescribed Nilemdo by highlighting ezetimibe’s mechanism of action, likely…
PMCPA found Galapagos’ Jyseleca website homepage banner ‘Strength of balance’ was ambiguous and insufficiently explained, breaching Clause 6.1. ‘Delivering breakthroughs…’ drew concern…
At ESC-HFA 2022, Ferinject banner ads ran on the congress site/Medscape and unintentionally reached UK HCPs for 60 days without certification by…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.